Merck out, Merck in
This article was originally published in Scrip
Elmar Schnee, head of Merck KGaA's pharmaceuticals unit, is stepping down to be replaced by the head of emerging markets at US rival Merck & Co, Stefan Oschmann. Mr Schnee was said to be leaving "for personal reasons". In line with his predecessor, Mr Oschmann will be responsible for both the Merck Serono and Consumer Health Care divisions of the German firm. Merck KGaA has suffered a series of clinical setbacks of late. Last month, the US FDA extended its review period for the company's multiple sclerosis pill cladribine, which was rejected by the EU's CHMP in September.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.